miércoles, 28 de octubre de 2015

10 Swiss startups you need to watch

Many aspects of Switzerland make it a good place to start a company. Here are 10 startups from Switzerland that you should keep an eye on

swisshero.jpg

The land known for its chocolate and watches is becoming increasingly known as a hotbed for new startups. Switzerland's startup scene is alive and thriving due to strong engineering schools and myriad possibilities for funding.

Yannick Guerdat is a member of the Alp ICT, an organization that seeks to grow business innovation in Switzerland. He said public-private partnerships are common in the country, and many startups can partner with universities as well. Additionally, most regions also have incubators, he said.

While investors typically don't take the same risks as investors in the US, he said, they are committed to the long term growth of the company.

"Beyond having the right people, technical solutions and infrastructure, the country's heritage in banking and confidentiality surely contributes to some extent," he said.

Guerdat said small business is integral to the Swiss economy. How fitting that the country where the World Wide Web got its start at CERN is now continuing its tradition of small business growth in technology and web-based businesses.

Here are 10 innovative new Swiss startups that are poised to do some big things.

1. ProtonMail

Former CERN employees developed ProtonMail, a secure email service that offers end-to-end encryption and other security features. The technology was developed in partnership with another research institution and even ProtonMail employees can't access user data. Forbes called it "the only e-mail system the NSA can't access."

2. Bestmile


Bestmile has built out a platform to manage fleets of autonomous vehicles. They don't build the vehicles themselves, but they provide the infrastructure for connecting and operating these vehicles. A clean UI makes the product easy to get started with and use.

3. Silent Circle

The secure smartphone known as the Blackphone was created by Swiss startup Silent Circle. The company's second iteration, the Blackphone 2, was released in September 2015. Potentially more secure than any other phone in the market, it runs a proprietary OS called Silent OS.

4. Dacuda

Dacuda turns your phone into a mobile 3D scanner. You can use the company's app 3DAround to take food photos, or its app called 3DSelfie to turn yourself into a 3D printed figurine. Their SLAM Scan technology applies robotic algorithms to recreate the images captured in three dimensions.

5. Threema

For the privacy and security conscious, Threema offers end-to-end encryption on all your messages, group chats, files, and status messages. Users are given a Threema ID to keep everything fully anonymous. The app also features a polling tool so users can poll their friends to help them make decisions.

6. Squirro

Squirro tackles a company's unstructured data to provide new insights into customer trends, service trends, and risk. A cloud solution, Squirro takes a look at both internal and external data to provide analysis.

7. Starmind

Starmind's "Brain Technology" is an AI tool that uses self-learning algorithms to make an information map of an organization. It can analyze and answer anonymous questions from employees, or point them to the top expert on a particular subject within their company.

8. HouseTrip

Similar to the increasingly popular Airbnb, Switzerland's HouseTrip helps users find and rent holiday homes in Europe, Asia, Africa, North America, South America, and Australia. The company went live in early 2010 and has since helped book millions of rooms.

9. Monetas


Monetas provides a platform for financial transactions to occur. The platform supports transaction in both national and digital currencies, and even offers Bitcoin integration. The company's website said it uses cryptographically secured digital notary to enable the transactions.

10. L.E.S.S.


L.E.S.S. develops and sells nan fiber lighting systems. The company offers applications in the automotive, industrial, and medical industries, among others. They provide both high and low-angle illumination systems.


jueves, 15 de octubre de 2015

In North America's Costliest City, Rich Chinese Take the Blame

  • > Vancouver voters look for political fix in Canadian election
  • > Coping with affordability crisis means roommates over families
James Hankle, a 50-something software engineer sporting blue jeans and a Green Party T-shirt, is explaining his fix for Vancouver’s runaway property prices when he’s interrupted by an eavesdropping passerby: “Stop allowing people from China to buy our houses and leave them vacant,” she says and walks away.
  • Despite British Columbia’s aversion to pipelines and affection for pot, housing affordability has pushed both aside as the number one issue raised by area residents in the run-up to Canada’s election this month. It’s not completely surprising given that Vancouver has become North America’s most expensive city.
  • Surging purchase prices have triggered protest movements like #donthave1million, started by a group of young professionals frustrated at being shut out of home ownership. They complain of having to delay starting families as they remain bunked in with roommates, often into their 30s and beyond.
  • The affordability issue speaks to broader campaign themes: the difficulty young people face getting established in the labor market, the economic anxieties of the middle class, growing concerns about income inequality, support for families with children. Residents also increasingly point fingers at wealthy Chinese immigrants and investors whose lavish embrace of the Pacific metropolis of 2.5 million has inspired reality TV shows with such gaudy names as “Ultra Rich Asian Girls in Vancouver.”
  • Vancouver, with its C$2.23 million ($1.7 million) average price tag for a detached home is playing an unusual role in the national election to be held Oct. 19. British Columbia is the only place where all four national parties are competitive -- the Conservatives, Liberals, New Democrats and Greens -- and, given the tightness of the race, its choices could spell the difference. As of now, the New Democrats and Liberals look likely to take some seats away from the Conservatives in the region, according to poll aggregator ThreeHundredEight.com.
  • Campaign Fodder
  • The top contenders for prime minister, incumbent Conservative Stephen Harper, Liberal Justin Trudeau and New Democrat Tom Mulcair, have all given voice on campaign stopovers to the city’s particular anxiety by promising they will, if elected, gather data on foreign ownership of its pricey condos and bungalows. “There are real concerns that foreign, non-resident real estate speculation is the reason some Canadian families find house prices beyond their budgets,” Harper said Aug. 12 in Vancouver. “That is a matter we can and should do something about.”
  • Though no expert on the subject, Hankle, like just about everyone else across the city, is obsessed with the topic and increasingly resigned to never owning a house himself. Standing in Yaletown, a one-time industrial site where nearby two-bedroom apartments can go for C$1.8 million, he calls on political parties competing for his vote to build more low-cost housing and introduce programs to guarantee people a livable minimum income.
  • He also picks up on the theme of the passing woman, saying governments need to begin collecting data on exactly who’s coming into the city and their impact on affordability. “There’s a huge concentration of wealth and it just isn’t sustainable,” he says.
  • Bubble Unburst
  • Unlike the U.S., Canada didn’t experience a housing price collapse with the global recession and has defied predictions ever since that the bubble is about to burst. With the exception of declines in 2009, 2012 and 2013, housing prices have risen in each of the past 15 years, with the cost doubling from August 2005 to 2015, according to the Real Estate Board of Greater Vancouver, out-pacing wage gains.
  • “Our big challenge is affordable housing,” said Vancouver Mayor Gregor Robertson, in a Sept. 25 interview at Bloomberg headquarters in New York. “It’s been difficult to deal with more affordable housing for a younger work force in particular.”
  • The Economist Intelligence Unit has named Vancouver the most expensive city to live in North America and a 2014 study by consultancy Demographia cited it as the second-least affordable housing market in the world after Hong Kong. Rising prices in Vancouver pushed housing affordability to “risky levels” in the second quarter as the costs of owning a bungalow rose to an unprecedented 86.9 percent of household income, an August report by RBC Capital Markets said.
  • “There’s national trend on affordability and it gets especially bleak in Vancouver,” said Paul Kershaw, an associate professor at the University of British Columbia who studies the impacts of public policy on housing. “The dynamic is signaling a change in the standard of living and home ownership that has been the norm for previous generations.”
  • Record Debt
  • Vancouver’s 25-to-34 year old cohort earns less and carries more debt than a generation ago, Kershaw said, meaning it now takes 10 working years to save for a down payment versus two years back then.
  • Although harder pressed, Vancouver families are in good company in borrowing more and more to get ahead. The debt of the average Canadian household now stands at a record 165 percent of disposable income, according to Statistics Canada, about 30 points higher than before the recession and matching the levels of U.S. debt when its housing market crashed. Still, in Vancouver at least, prices are galloping ahead so quickly, they “make it a stretch” for a typical household to get into the market.
  • “It’s possible to live decently here as long as you’re single and don’t have dependents,” said Scott McFadyen, a 38-year-old audio designer in the video game industry who moved to Vancouver from Alberta. “Truthfully, I’m thinking twice about starting a family here.”



miércoles, 14 de octubre de 2015

2,000% Drug Price Surge Is a Side Effect of FDA Safety Program (BusinessWeek)

> Drugs used for decades are licensed, branded in safety drive
> Prices jump as makers given monopolies on approved versions

Colchicine, a gout remedy so old that the ancient Greeks knew about its effects, used to cost about 25 cents per pill in the U.S. Then in 2010 its price suddenly jumped 2,000 percent.

That’s just one of the side effects of a U.S. Food and Drug Administration plan to encourage testing of medicines that have been around longer than the modern FDA itself, and so have never gotten formal approval. Companies that do the tests are rewarded with licenses that can temporarily give them monopoly pricing power as most rivals are eased or kicked off the market. The result has been a surge in the cost of drugs used in treatments from anesthesia to heart surgery and eye operations.

It can bring big paydays for the producers. URL Pharma, the small Philadelphia drugmaker granted rights over colchicine, was bought for $800 million by Takeda Pharmaceutical Co. in 2012. Asia’s biggest drugmaker has since brought in $1.2 billion in revenue from the branded drug, Colcrys, which went on the market at a wholesale price of almost $6 a pill. Takeda says testing for FDA approval made the drug safer.

But patients and hospitals are feeling the pinch, and politicians have begun to notice. Hillary Clinton’s recent promise to address the issue sent pharmaceutical stocks plunging. Critics say the FDA plan lets entrepreneurs make windfall profits on drugs where there was never much concern about safety or efficacy.

In many cases, the program “almost had the opposite effect as intended,” said Joseph Biskupiak, a professor at the University of Utah College of Pharmacy. “The only drugs that got studied are the ones that don’t have a problem.”

The FDA’s rationale is that some drugs have never been measured against modern safety standards. The program “has been a success” that has removed dangerous drugs from the market, said Michael Levy, deputy director in the compliance office of the FDA’s drug evaluation unit.

The agency acknowledges that approving branded versions of old generic drugs may make them more expensive when a sole manufacturer remains to make a medication, but says that’s outside its remit. “FDA does not regulate according to economic factors, nor do we have control over drug pricing,” spokesman Christopher Kelly said.

The FDA program, which got under way in 2006, is only one reason why prices of old generic drugs have risen. Others include mergers that reduced competition, and a business strategy by some drugmakers of acquiring niche medicines and raising prices sharply, even without any rebranding.

‘Business Model’

A price survey of more than 21,000 generic drugs for Bloomberg News by DRX, a unit of Connecture Inc. that tracks drug prices, found that more than 3,500 have doubled or more since late 2007, ranging from basic chemotherapy medicines to old antibiotics.

John Lewin, director of the critical care and surgical pharmacy at Johns Hopkins Hospital in Baltimore, said in many cases there are no obvious benefits to offset the higher prices.
“We’re not paying for innovation, we’re not paying for fewer side effects, and we’re not paying for better care,” he said. “We’re paying for somebody’s business model to make a profit.”

Glenn Spann, a longtime user of colchicine for his gout, says he never paid more than $10 a prescription -- until he was hit with a $300 bill when his insurer stopped covering the treatment after its price spiked. “There is no justification for it,” said Spann, a 55-year-old self-employed artist in Culver City, California. “There is nothing different except the marketing,” and the ownership.

Shares Rise

Investors who bet on the industry have benefited from the sales increases. Since the end of 2009, a Bloomberg Intelligence index of specialty-generic drugmakers has almost quadrupled -- gaining about four times as much as the S&P 500 Index.


It was outperforming this year, too -- until last month, when Clinton tweeted that “price gouging” in some specialty drugs was “outrageous.


Since then, shares in Flamel Technologies SA are down about 25 percent. The company won FDA approval in May 2013 for Bloxiverz, a brand-name version of neostigmine, used to reverse the effects of anesthesia after surgery. According to DRX, Bloxiverz costs more than six times as much as its unapproved predecessors, which have been removed from the market under what the FDA says was a voluntary commitment by their makers.

Products like Bloxiverz are designed “to produce cash flow,” Michael Anderson, Flamel’s chief executive officer, told investors in June. Flamel’s revenue soared to $49.8 million in the second quarter of 2015, from $4.3 million the previous year.

The price of Bloxiverz reflects the costs of getting it approved, including an FDA filing fee of more than $2 million, Bob Yedid, a Flamel spokesman, said by phone. “We’ve been very careful not to have what I’ll call ‘irresponsible’ price increases,” he said. Flamel uses its profit to invest in developing new drugs.

Vasopressin Prices

Another drug to jump in price is vasopressin, a blood-vessel constricting agent used in emergencies. Vasostrict, a branded version approved last year and owned by Endo International Plc, costs $116 per milliliter wholesale, more than 10 times the wholesale price of unapproved versions three years ago, according to DRX.

Such increases are causing problems for hospitals. Johns Hopkins has set up a task force to identify which established drugs could be next in line for the FDA program.

Tenet Healthcare Corp., the fourth-largest U.S. operator with almost 500 treatment centers, says it’s started refrigerating vasopressin because that can increase its shelf-life to two years from less than 12 months, so it doesn’t have to replace the drug as often.

Vasostrict was developed by Par Pharmaceutical Holdings Inc., which was bought by Endo last month. Keri Mattox, senior vice president at Endo, said in an e-mail that Par “invested significant time and resources to demonstrate the safety and efficacy of its reformulated product.” The company’s reformulation of the drug "corrected key overage and necessary refrigeration attributes of the old unapproved product," she said.

Benefits of Testing

In the case of colchicine, the FDA and Takeda say the tests yielded benefits. Unapproved versions had labels that recommended dangerously high doses or neglected potential side effects, the FDA’s Levy said. The approved version hit the market in 2009, and the next year the FDA moved to take the lower-cost versions off the market. The testing process has “significantly changed the manner in which colchicine is prescribed,” said Linda Calandra, a Takeda spokeswoman.

But Aaron Kesselheim, a researcher at Harvard Medical School, studied colchicine prescriptions before and after the FDA intervention, and found no difference in the rate of doctors prescribing the medication along with another drug that could have dangerous interactions. His survey was published in April in the Journal of General Internal Medicine.

“This is a good example of market exclusivity being given to a company that didn’t really deserve it,” Kesselheim said. The company tested “a dosing regimen that people already knew about -- and showed it worked, which everyone already knew.”

Calendra said Takeda can’t comment on studies conducted by outside parties. She said the testing had produced new dosing and safety information.

Bringing drugs that predate the modern FDA under regulation isn’t a bad idea in principle, Kesselheim said. But “the trade-off you get, of ridiculously higher prices, I don’t think is a great trade-off.”